Indicated for the treatment of chronic hepatitis B virus infection in adults and adolescents (aged 12 years and older with body weight at least 35 kg): 🦠 Compensated Liver Disease: Effective for HBeAg-positive and HBeAg-negative patients. 🔄 Switching Therapy: Ideal for patients transitioning from Tenofovir Disoproxil Fumarate (TDF) due to bone or renal concerns.

Dosage and administration

Packaging: Bottle of 30 tablets (1-month supply). ⚠️ DOSAGE PROTOCOL: 💊 Standard Dose: One tablet (25 mg) taken once daily. 🍽️ Administration: Must be taken WITH FOOD. Food increases the absorption and efficacy of the drug. ⏰ Consistency: Do not miss doses. Adherence is critical to prevent drug resistance. 📅 Duration: Often indefinite (long-term). Do not stop taking without consulting a hepatologist, as severe acute exacerbation of Hepatitis B may occur.

Severe hypersensitivity to Tenofovir Alafenamide. Breastfeeding (safety not established). Children under 12 years of age. Patients with end-stage renal disease (CrCl < 15 mL/min) who are not receiving chronic hemodialysis.

Tafnext is generally well-tolerated: 🤕 Common: Headache, fatigue. 🤢 Gastrointestinal: Nausea, abdominal pain (usually mild). 📉 Advantage: Significantly lower risk of osteoporosis and renal tubulopathy compared to older Tenofovir (TDF) formulations.

Tafnext — Tenofovir Alafenamide 25 mg, 30 product-page.units_short, Aprazer

100% original product

Active ingredient

Tenofovir Alafenamide

Manufacturer

Aprazer

Dosage 25 mg

Dosage form Tablets

Tablets per pack 30

Tafnext (Tenofovir Alafenamide) Tablets

Name: Tafnext
Brand: Aprazer
SKU: PROD-125
Price: 1011 UAH
Availability: InStock

1011₴ ~~1275₴~~ -21%

Tafnext (Tenofovir Alafenamide 25 mg) is a next-generation antiviral medication, a generic version of Vemlidy, produced by Aprazer.

It is a Nucleotide Reverse Transcriptase Inhibitor (NRTI) designed specifically for the treatment of Chronic Hepatitis B (HBV). TAF is an advanced prodrug of Tenofovir that delivers the active substance directly to hepatocytes (liver cells) more efficiently than the older formulation (TDF).

Key Benefit ("Kidney & Bone Safety"):

Because it works at a much lower dose (25 mg vs 300 mg), Tafnext has significantly less toxicity to the kidneys and bones. This makes it the preferred choice for long-term maintenance therapy in aging populations or those with renal risks.

✅ Goal: Potent viral suppression with an improved safety profile.

Indicated for the treatment of chronic hepatitis B virus infection in adults and adolescents (aged 12 years and older with body weight at least 35 kg):

🦠 Compensated Liver Disease: Effective for HBeAg-positive and HBeAg-negative patients.
🔄 Switching Therapy: Ideal for patients transitioning from Tenofovir Disoproxil Fumarate (TDF) due to bone or renal concerns.

Packaging: Bottle of 30 tablets (1-month supply).

⚠️ DOSAGE PROTOCOL:

💊 Standard Dose: One tablet (25 mg) taken once daily.
🍽️ Administration: Must be taken WITH FOOD. Food increases the absorption and efficacy of the drug.
⏰ Consistency: Do not miss doses. Adherence is critical to prevent drug resistance.
📅 Duration: Often indefinite (long-term). Do not stop taking without consulting a hepatologist, as severe acute exacerbation of Hepatitis B may occur.

Severe hypersensitivity to Tenofovir Alafenamide.
Breastfeeding (safety not established).
Children under 12 years of age.
Patients with end-stage renal disease (CrCl < 15 mL/min) who are not receiving chronic hemodialysis.

Tafnext is generally well-tolerated:

🤕 Common: Headache, fatigue.
🤢 Gastrointestinal: Nausea, abdominal pain (usually mild).
📉 Advantage: Significantly lower risk of osteoporosis and renal tubulopathy compared to older Tenofovir (TDF) formulations.